Page last updated: 2024-12-06
2-chloro-4,6-diamino-s-triazine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 18831 |
| CHEMBL ID | 1872965 |
| CHEBI ID | 27726 |
| SCHEMBL ID | 197055 |
| MeSH ID | M0244686 |
Synonyms (86)
| Synonym |
|---|
| BB 0253749 |
| nsc-680830 |
| nsc7965 |
| s-triazine,4-diamino-6-chloro- |
| ent 50982 |
| 2-chloro-4,6-diaminotriazine |
| 1,5-triazine-2,4-diamine, 6-chloro- |
| g 28273 |
| nsc-7965 |
| s-triazine, 2,4-diamino-6-chloro- |
| 1,3,5-triazine-2,4-diamine, 6-chloro- |
| desdiethyl simazine |
| desdiisopropyl propazine |
| desethyldesisopropyl atrazine |
| 2-chloro-4,6-diamino-1,3,5-triazine |
| CHEBI:27726 , |
| 2-chloro-4,6-diamino-s-triazine |
| 2,4-diamino-6-chloro-1,3,5-triazine |
| STK505614 |
| 6-chloro-1,3,5-triazine-2,4-diamine |
| nsc680830 |
| 2,4-diamino-6-chloro-s-triazine |
| C06560 |
| deisopropyldeethylatrazine |
| 3397-62-4 |
| 2-chloro-4,6-diamino-1,3,5-triazine, 95% |
| 2-chloro-4,6-diamino-1,3,5-triazine, analytical standard |
| NCGC00163870-03 |
| NCGC00163870-01 |
| NCGC00163870-02 |
| 6-chloro-2,4-diamino-1,3,5-triazine |
| desethyl-desisopropyl-atrazine |
| caat |
| NCGC00163870-04 |
| dact |
| ai3-50982 |
| 2-caat |
| unii-kvz1hmr84l |
| nsc 7965 |
| einecs 222-260-6 |
| ccris 3553 |
| deisopropyldeethyl atrazine |
| dideethylsimazine |
| desethyldesisopropylatrazine |
| chloroammeline |
| nsc 680830 |
| deethyldeisopropylatrazine |
| atramod |
| kvz1hmr84l , |
| NCGC00255005-01 |
| dtxcid9017806 |
| cas-3397-62-4 |
| dtxsid1037806 , |
| tox21_301105 |
| A822030 |
| 6-chloro-[1,3,5]triazine-2,4-diamine |
| AKOS005172071 |
| GEO-00671 |
| FT-0634830 |
| 4,6-diamino-2-chloro-s-triazine |
| bis(amino)-2-chloro-s-triazine, 4,6- |
| g-28273 |
| ent-50982 |
| 2,4-diamino-6-chlorotriazine |
| SCHEMBL197055 |
| 2,4-diamino-6-chloro-1,3.5-triazine |
| 2-chloro-4,6-diamino-1, 3,5-triazine |
| 2,4-bis(amino)-6-chloro-1,3,5-triazine |
| 2,6-diamino-4-chloro-s-triazine |
| W-200311 |
| CHEMBL1872965 |
| c3h4cln5 |
| mfcd00006054 |
| atrazine-desethyl-desisopropyl |
| atrazine-desethyl-desisopropyl, pestanal(r), analytical standard |
| desethyl-desisopropyl atrazine |
| EN300-260210 |
| BS-16918 |
| Q27103287 |
| 2-chloro-4,6-bis(amino)-1,3,5-triazin |
| SB73697 |
| D70560 |
| atrazine-desethyl-desisopropyl 100 microg/ml in acetonitrile |
| CS-W018245 |
| Z57061149 |
| PD065576 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " An adequate description of the uptake and bioavailability of absorbed ATRA also required inclusion of additional oxidative metabolic clearance of ATRA to the mono-dealkylated metabolites occurring in GI a tract compartment." | ( Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. Andersen, ME; Cranmer, BK; Hanneman, WH; McMullin, TS; Tessari, JD, 2007) | 0.34 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Intracellular NE was significantly reduced at these same concentrations of deethylchlorotriazine at 24 h while the concentration of NE in PC12 cells exposed to deisopropylchlorotriazine was not altered at any dosage or time point measured." | ( Alteration of catecholamines in pheochromocytoma (PC12) cells in vitro by the metabolites of chlorotriazine herbicide. Cooper, RL; Das, PC; McElroy, WK, 2001) | 0.31 |
| " While no significant delays in pubertal development were observed in two separate dose-response studies with doses ranging up to 183 mg/kg (OH-ATR), a minor but statistically significant delay in the onset of puberty in a pilot study using OH-ATR raises the possibility that an effect might occur following exposure to higher doses." | ( Pubertal development in female Wistar rats following exposure to propazine and atrazine biotransformation by-products, diamino-S-chlorotriazine and hydroxyatrazine. Cooper, RL; Ferrell, JM; Laws, SC; Stoker, TE, 2003) | 0.32 |
| " Here, we develop a set of physiologically based pharmacokinetic (PBPK) models that describe the influence of oral absorption and oxidative metabolism on the blood time course curves of individual chlorotriazines (Cl-TRIs) in rat after oral dosing of ATRA." | ( Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. Andersen, ME; Cranmer, BK; Hanneman, WH; McMullin, TS; Tessari, JD, 2007) | 0.34 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| chloro-1,3,5-triazine | A member of the class of 1,3,5-triazines that is 1,3,5-triazine substituted by at least one chloro group at unspecified position. |
| diamino-1,3,5-triazine | Any member of the class of 1,3,5-triazines that consists of a 1,3,5-triazine skeleton substituted by two amino groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (8)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 43.6412 | 0.0002 | 21.2231 | 8,912.5098 | AID743035 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.0178 | 0.0002 | 14.3764 | 60.0339 | AID588532 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 0.0028 | 0.3758 | 27.4851 | 61.6524 | AID588527 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 30.8956 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 0.0490 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 5.6234 | 0.0100 | 39.5371 | 1,122.0200 | AID588545 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 891.2510 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 22.3872 | 0.0023 | 19.5956 | 74.0614 | AID651743 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (19)
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.96) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||